Cancer Research and Treatment

Original Articles

Breast cancer

Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor–Positive Metastatic Breast Cancer: Seul-Gi Kim, Min Hwan Kim, Sejung Park, Gun Min Kim, Jee Hung Kim, Jee Ye Kim, Hyung Seok Park, Seho Park, Byeong Woo Park, Seung Il Kim, Jung Hwan Ji, Joon Jeong, Kabsoo Shin, Jieun Lee, Hyung-Don Kim, Kyung Hae Jung, Joohyuk Sohn; Cancer Res Treat. 2023;55(4):1198-1209. Published online April 11, 2023; DOI: https://doi.org/10.4143/crt.2022.1543

Abstract PDF Supplementary Material PubReader ePub

Purpose
Frequent neutropenia hinders uninterrupted palbociclib treatment in patients with hormone receptor (HR)–positive breast cancer. We compared the efficacy outcomes in multicenter cohorts of patients with metastatic breast cancer (mBC) receiving palbociclib following conventional dose modification or limited modified schemes for afebrile grade 3 neutropenia.
Materials and Methods
Patients with HR-positive, human epidermal growth factor receptor 2–negative mBC (n=434) receiving palbociclib with letrozole as first-line therapy were analyzed and classified based on neutropenia grade and afebrile grade 3 neutropenia management as follows: group 1 (maintained palbociclib dose, limited scheme), group 2 (dose delay or reduction, conventional scheme), group 3 (no afebrile grade 3 neutropenia event), and group 4 (grade 4 neutropenia event). The primary and secondary endpoints were progression-free survival (PFS) between groups 1 and 2 and PFS, overall survival, and safety profiles among all groups.
Results
During follow-up (median 23.7 months), group 1 (2-year PFS, 67.9%) showed significantly longer PFS than did group 2 (2-year PFS, 55.3%; p=0.036), maintained across all subgroups, and upon adjustment of the factors. Febrile neutropenia occurred in one and two patients of group 1 and group 2, respectively, without mortality.
Conclusion
Limited dose modification for palbociclib-related grade 3 neutropenia may lead to longer PFS, without increasing toxicity, than the conventional dose scheme.

Citations

Citations to this article as recorded by

Palbociclib in Patients With HR+/HER2− Advanced or Metastatic Breast Cancer and Bone-Only Metastasis: A Systematic Literature Review
Joyce O’Shaughnessy, Nusrat Jahan, Anna Louise Barry, Rebecca Jean Watters, Beata Korytowsky, Diana Avery, Vinay Pasupuleti, Andrew Proctor
Clinical Breast Cancer.2026; 26(6): 113. CrossRef
Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies
Hui-Chen Su, Ho-Wei Lin, Ka-Wai Tam
Targeted Oncology.2025; 20(1): 71. CrossRef
Palbociclib Is Safe for Breast Cancer Patients With Mild Hepatic Impairment: A Multicenter Retrospective Study Using Real‐World Data
Alieke K. Bos, Annelieke E.C.A.B. Willemsen, Loes E. Visser, Lennart J. Stoker, Jurjen S. Kingma, Mirjam K. Rommers, Emile M. Kuck, Paul D. van der Linden, Merel van Nuland
Clinical Pharmacology & Therapeutics.2025; 117(4): 1115. CrossRef
Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2− advanced/metastatic breast cancer: updated systematic review
Nadia Harbeck, Adam Brufsky, Chloe Grace Rose, Beata Korytowsky, Connie Chen, Krista Tantakoun, Endri Jazexhi, Do Hoang Vien Nguyen, Meaghan Bartlett, Imtiaz A. Samjoo, Timothy Pluard
Frontiers in Oncology.2025;[Epub] CrossRef
Adverse Event Costs and Cost-Effectiveness Analyses of Anticancer Drugs
Mingye Zhao, Taihang Shao, Yue Yin, Hongshu Fang, Hanqiao Shao, Wenxi Tang
JAMA Network Open.2025; 8(5): e2512455. CrossRef
Palbociclib treatment in patients with HR+/HER2− advanced or metastatic breast cancer and visceral metastasis: A systematic literature review
Julia C. Radosa, Sara López-Tarruella Cobo, Johanna Dzieran, Esther Glastetter, Connie Chen, Melissa Lingohr-Smith, Vinay Pasupuleti, Adam Brufsky
The Breast.2025; 84: 104569. CrossRef
Palbociclib

Reactions Weekly.2023; 1988(1): 138. CrossRef

10,269 View
311 Download
6 Web of Science
7 Crossref

Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma: Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha; Cancer Res Treat. 2019;51(4):1578-1588. Published online April 16, 2019; DOI: https://doi.org/10.4143/crt.2018.671

Abstract PDF PubReader ePub

Purpose
Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naïve Asian patients with metastatic/recurrent nccRCC.
Materials and Methods
From January 2008 to July 2017, data of treatment-naïve, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end-point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus.
Results
Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54%) were papillary type, and other histology subtypes included 11 chromophobes (25%), two collecting ducts (5%), one Xp11.2 translocation (2%), and six others (14%). The median PFS and OS were 7.6 months and 17.6 months, res-pectively. ORR was 11% and disease control rate was 83%. Patients with prior nephrectomy had longer PFS (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.06 to 0.42; p < 0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p < 0.001). Compared to favorable/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12; p=0.005]) and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56; p=0.015]).
Conclusion
Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate-risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events.

Citations

Citations to this article as recorded by

Deciphering molecular pathways in urological cancers: A gateway to precision therapeutics
Kiavash Hushmandi, Najma Farahani, Behzad Einollahi, Shokooh Salimimoghadam, Mina Alimohammadi, Liping Liang, Le Liu, Gautam Sethi
Journal of Advanced Research.2026; 81: 967. CrossRef
Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database
Lifeng Dan, Zhenyu Liu, Zecang Zhao, Yueli Ran, Jiangtao Zhou, Dongyang Li, Renjie Zhou, Shuai Su, Zhikang Yin
Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(9): 13661. CrossRef
A perspective on the application of macrocyclic design strategies in antitumor drugs
Yan-Hong Li, Yu-Kang Lin, Jian-Fan Cai, Zhong-Kai Zou, Pei-Liang Zhao
Bioorganic Chemistry.2025; 156: 108190. CrossRef
Zebularine showed anti-tumor efficacy in clear cell renal cell carcinoma
Haoyu Xu, Senlin Peng, Junwu Li, Yuanyuan Bai, Guozhi Zhao, Simin Liang, Wei Tang
Frontiers in Pharmacology.2025;[Epub] CrossRef
Molecular and therapeutic landscape of non-clear cell renal carcinoma
Prerna R. Nepali, Ahmed Eraky, Kennedy E. Okhawere, Navneet Dogra, Reza Mehrazin, Ketan Badani, Natasha Kyprianou
Nature Reviews Urology.2025; 22(11): 735. CrossRef
Efficacy of temsirolimus versus pazopanib in the treatment of advanced renal cell carcinoma: a meta-analysis
Yanni Liu
American Journal of Clinical and Experimental Urology.2025; 13(4): 272. CrossRef
Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options
Nathaniel R. Wilson, Yusuf Acikgoz, Elshad Hasanov
International Journal of Cancer.2024; 154(6): 947. CrossRef
Cancer stem cells and angiogenesis
Yanru Yang, Jingyu Guo, Mingyang Li, Guangxin Chu, Hai Jin, Jing Ma, Qingge Jia
Pathology - Research and Practice.2024; 253: 155064. CrossRef
Renal cancer: signaling pathways and advances in targeted therapies
Aimin Jiang, Jinxin Li, Ziwei He, Ying Liu, Kun Qiao, Yu Fang, Le Qu, Peng Luo, Anqi Lin, Linhui Wang
MedComm.2024;[Epub] CrossRef
Effectiveness of systemic treatments for advanced non-clear cell renal cell carcinoma: a systematic review and meta-analysis
Yaping Zhang, Jian Chen, Xiaoyan Wang, Hui Wang, Xiaoli Chen, Jianfeng Hong, Hongming Fang
Frontiers in Oncology.2024;[Epub] CrossRef
Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China
Jingyang Lin, Qingxia Fang, Xiaochun Zheng, Meng Li
PLOS ONE.2023; 18(2): e0281402. CrossRef
Targeted Literature Review of Outcomes to Initial Systemic Therapy for Advanced/Metastatic Non-Clear Cell Renal Cell Carcinoma in Observational Studies
Shawna R. Calhoun, Manish Sharma, Chung-Han Lee
Kidney Cancer.2023; 7(1): 123. CrossRef

10,775 View
185 Download
13 Web of Science
12 Crossref

First
Prev
Page of 1
Next
Last

Search